SRMS
| Official symbol: | SRMS |
| Full name: | src-related kinase lacking C-terminal regulatory tyrosine and N-terminal myristylation sites |
| Location: | 20q13.33 |
| Also known as: | PTK70, SRM, dJ697K14.1, C20orf148 |
| Entrez ID: | 6725 |
| Ensembl ID: | ENSG00000125508 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
| Expression restricted in 3 cancer type(s) | | Cancer specific in breast cancer subtype (ER; Her2; LumA; LumB) |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.32 | | Gscore (Del): | 0.00 |
|
|
| Recurrently amplified in 1 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | NA |
|
|
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 23.05 (Percentile rank: 49.70%) |
| PubTator score: | 2.83 (Percentile rank: 21.20%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Clinical PrecedenceTargets with drugs in phase II or above; Pre-clinical targets |
| Tractability (antibody): | |
